A Cancer Wake-Up Call

What this webinar covers

Dr. Goodenowe opens by acknowledging that cancer is a sensitive topic and that every person’s situation is different — which is why, in his words, you need a skilled practitioner alongside you rather than a webinar. What follows is a lecture on mechanism: what a cancer cell actually is, why he believes cancers announce themselves biochemically long before they are detectable, what surgery and chemotherapy do and do not change, and what he means by restoring health before and after a diagnosis.

He also spends real time on a subject cancer patients are rarely briefed on in detail — the long-term neurological cost of chemotherapy, and what it takes for the brain to recover afterward.

What cancer is, in his framing

Dr. Goodenowe’s central metaphor runs through the entire lecture, and it is worth understanding because everything else builds on it. A cancer cell, in his description, is a cell that has lost its purpose.

Your body, he explains, is a community of roughly thirty-seven trillion cells — more operational units than human civilization has people, and not centrally controlled. Each cell has a specialized job it adapted into. A healthy organ is a functioning neighborhood: people have work, the work is distributed, resources circulate. In his phrasing, a cell with a job and a purpose does not have time to be a cancer cell.

The first step toward cancer, then, is that a cell becomes unable to do its job — through environmental damage, genetic predisposition, or both. At that point it either dies or finds another way to survive. Dr. Goodenowe is emphatic that this is not a moral event: cells do not choose to become cancerous; they are either forced to or allowed to. His analogy is a professional who loses the ability to practice, develops an addiction, drifts into dealing to survive, and eventually becomes unrecognizable as what he started out as.

That, he argues, is the part conventional framing misses. One rogue cell is not a disease — it is a normal event happening in everyone. For it to become cancer, the surrounding community has to be too weak to contain it. Cancer, in his summary, is not an infection, not a virus, and not random: it is a logical and predictable sequence of events.

From there he lays out three options once cancer is established: treat aggressively with chemotherapy, radiation and surgery and hope a healthy neighborhood emerges afterward; rebuild the neighborhood so that it becomes inhospitable to cancer; or combine the two. He is explicit throughout that the first option is sometimes necessary. His argument is with stopping there.

The prodrome: cancer as a foreseeable event

The core of Dr. Goodenowe’s career, by his account, has been the study of prodromes — the biochemical state that precedes disease in people who currently appear healthy. He describes nearly three decades spent looking at asymptomatic individuals to find who was, in his words, living with a ticking time bomb.

The measurement technology behind this is ion cyclotron mass spectrometry, one of his original patents, which allows thousands of biochemical molecules in blood to be measured simultaneously rather than one test at a time. When those measurements are plotted, he says, people with similar biochemistry cluster together — and people with cancer cluster separately from healthy controls.

One finding he returns to repeatedly: when you look at the full picture, cancer is overwhelmingly a state of biochemical deficiency rather than excess. Far more molecules are depleted than elevated, and that pattern holds across cancer types. Plasmalogens are among the depleted molecules in virtually all of them.

Across colon, pancreatic and ovarian cancer, Dr. Goodenowe presents his own trials showing that a blood biochemical signature separates people who go on to develop these cancers from those who do not — with the people lacking that signature showing dramatically lower incidence. His summary of the pattern is blunt: no prodrome, no disease.

What surgery and chemotherapy do not address

This is the section that gives the webinar its title, and it is the part Dr. Goodenowe calls his own turning point toward restorative medicine.

In colon cancer, he ran a study expecting that removing the tumor would return the biomarkers to normal — the assumption being that the tumor was consuming them. Twelve weeks after surgery, he says, the markers had not moved. He repeated the study at a different university and got the same result. His conclusion: “We’re not detecting cancer. We’re detecting people who get cancer.”

The same pattern appears in breast cancer. In work he published with Kyoto University, plasmalogen deficiency and elevated fatty acid elongation distinguished women with breast cancer at roughly ninety-three percent accuracy before treatment — and measured again after surgery and chemotherapy, plasmalogen levels were the same or lower. Across a larger set of cancers studied with Chiba University, he reports treatment often reduced them further.

Why that matters, in his argument, is recurrence. He cites long-term follow-up in which a substantial share of breast cancer survivors died of breast cancer more than a decade after being declared cancer-free, with relative risk many times that of women who never had it. His framing:

Chemo brain: the cost that gets discussed least

Dr. Goodenowe did not coin the term — it appears throughout the published literature — but he argues its severity is understated in patient conversations. He cites a 2022 review describing central nervous system effects of chemotherapy including memory deficits and cognitive disorders, with the frequency in breast cancer patients reaching as high as eighty percent.

Reviewing the mechanism studies for common chemotherapeutic agents, he notes that the listed mechanism is the same one over and over: stimulation of neuroinflammation. His conclusion is that brain inflammation from chemotherapy is not a possibility but a predictable consequence — visible on MRI as white matter volume expansion months after treatment ends.

His point is not that chemotherapy should be avoided. It is that the damage is foreseeable, and that foreseeable damage can be planned for. In his analogy, sending a drone into the drug house down the street may well be necessary — but you do not then walk away and leave the neighborhood holding the bag. Recovery of white matter, he notes, has a specific biochemical requirement: myelin is heavily plasmalogen-dependent, and adults are not replenishing plasmalogens from diet the way an infant does from breast milk.

Where the evidence actually stands

In the Q&A, Dr. Goodenowe is asked directly whether there are studies showing that oral plasmalogen supplementation reduces cancer risk or recurrence. His answer is worth quoting plainly, because it sets the boundary around everything above:

Asked what his prior research consisted of, he describes it as epidemiological case-control monitoring — pattern analysis of biochemistry in large populations. A structured clinical trial of restoration as a cancer intervention, he says, has not been done.

He also explains why he thinks that gap exists, and it is a structural argument rather than a conspiratorial one. The FDA approval pathway was built for single novel molecules with single indications — drugs that are not part of human biochemistry to begin with. A multi-component restoration protocol built from nutrients the body already uses does not fit that pathway. As he puts it, there is no approval route for a recipe.

The restorative approach

The last third of the lecture moves from mechanism to what Dr. Goodenowe would actually do. The through-line is that most conventional medicine treats disease at the point of failure — identify the disease, treat the disease, send the patient home — without addressing why that person became susceptible. In his description, that is patching a bald tire and waiting for the next flat.

Restoring health, in his framing, means something different: identifying the deviations from healthy biochemistry that precede disease, and correcting them before they become one.

Susceptibility and trigger

One of the more grounded moments in the Q&A comes when Dr. Goodenowe is asked how far this can be pushed. His answer sets the limit himself: every disease has two components, a susceptibility and a trigger. You can reduce your triggers somewhat by how you live. You can reduce your susceptibility considerably by restoring biochemistry. But you cannot reach zero.

“I can make you as healthy as possible,” he says, “but if you step in front of a bus, I’m sorry.” If the disease pressure is strong enough, it overcomes anything you are doing.

Asked whether spontaneous remission exists, he says he believes it does — and that it is probably not spontaneous at all, but the visible result of a biochemical change that happened first. Asked whether a prodrome for one cancer implies prodromes for others, he says they overlap substantially, with some tissue-specific patterns: choline deficiency weighted toward pancreatic and liver, GTA deficiency toward colon and pancreatic, fatty acid elongation toward breast and ovarian, and plasmalogen depletion across essentially all of them.

His closing argument is the one he would presumably want a viewer to leave with: that health itself is measurable, that deviation from it is measurable, and that measuring it carries no downside. In his words — there is no negative side effect of health.